Publication:
The Pharmaceutical Sector in Ghana

Simple item page
dc.contributor.authorGyansa-Lutterodt, Martha
dc.contributor.authorSeiter, Andreas
dc.date.accessioned2017-09-06T19:42:01Z
dc.date.available2017-09-06T19:42:01Z
dc.date.issued2009-11
dc.description.abstractMain pharmaceutical policy goals in Ghana are access to essential medicines for everybody, quality assurance for all drugs on the market, a functioning and efficient supply chain as well as rational use of medicines by professionals and patients. There is also a commitment to strengthen the domestic pharmaceutical industry, outlined under health industry in the national health policy. The National Health Insurance System (NHIS) has significantly improved access to medicines for insured patients, measured in increased utilization of facilities and rapidly growing turnover of revolving drug funds. The risk is now that non-rational prescribing and fraud lead to a growing medicine bill that threatens financial sustainability of NHIS. On the other hand, National Health Insurance Authority (NHIA) has the resources and purchasing power to influence provider behavior as well as the market in terms of quality and price. The purpose of this policy note is to provide a compact overview of the situation, trends and opportunities in the pharmaceutical sector in Ghana as relevant to the strategic objectives in the five year program of work. It summarizes data from a number of recent studies and reports that were done by a range of partners inside and outside the country as well as discussions with key stakeholders in the sector. The intent is to give decision makers up-to-date background information and provide some suggestions for specific policy initiatives designed to achieve the work program objectives, with a particular focus on the role health insurance can play to stabilize and improve service delivery, increase access to quality medicines and promote rational use. The overall legal framework for the pharmaceutical sector is set by the Food and Drugs Law from 1992, amended by Act 523 in 1996. It defines the role of the food and drugs board as separate entity under control of the Ministry of Health (MOH), responsible for regulating the sector. The Food and Drugs Board (FDB) also runs the official drug quality control laboratory that is in charge of testing quality samples obtained from manufacturers, importers, distributors or other sources. The FDB is also working on an improvement of its public website in an effort to strengthen communication with the general public to increase transparency and improve governance.en
dc.identifierhttp://documents.worldbank.org/curated/en/734211468030342727/The-pharmaceutical-sector-in-Ghana-policy-note
dc.identifier.doi10.1596/28117
dc.identifier.urihttps://hdl.handle.net/10986/28117
dc.languageEnglish
dc.language.isoen_US
dc.publisherWorld Bank, Washington, DC
dc.rightsCC BY 3.0 IGO
dc.rights.holderWorld Bank
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/igo
dc.subjectABUSE
dc.subjectACCESS TO HEALTH CARE
dc.subjectACCOUNTABILITY
dc.subjectADEQUATE TREATMENT
dc.subjectADHERENCE TO TREATMENT
dc.subjectADVERSE EVENTS
dc.subjectADVERTISING
dc.subjectAIDS CONTROL
dc.subjectAIDS CONTROL PROGRAM
dc.subjectAIDS RELIEF
dc.subjectANTIBIOTICS
dc.subjectAVAILABILITY OF DRUGS
dc.subjectBED NETS
dc.subjectBIDDING
dc.subjectBRAND
dc.subjectBRAND NAME
dc.subjectBRAND NAMES
dc.subjectBRANDS
dc.subjectBUDGETING
dc.subjectCAPITAL MARKETS
dc.subjectCASE MANAGEMENT
dc.subjectCASH FLOW
dc.subjectCENTRAL MEDICAL STORES
dc.subjectCERTIFICATION
dc.subjectCHEMISTS
dc.subjectCIF
dc.subjectCITIZENS
dc.subjectCLINICAL PHARMACOLOGY
dc.subjectCLINICAL TRIALS
dc.subjectCLINICS
dc.subjectCOMMODITIES
dc.subjectCOMPETITIVE BIDDING
dc.subjectCORRUPTION
dc.subjectCOUNTERFEIT DRUGS
dc.subjectCOUNTRIES OF ORIGIN
dc.subjectDEBT FORGIVENESS
dc.subjectDECENTRALIZATION
dc.subjectDECISION MAKING
dc.subjectDEVELOPING COUNTRIES
dc.subjectDIAGNOSIS
dc.subjectDISEASES
dc.subjectDOMESTIC MANUFACTURERS
dc.subjectDOMESTIC MARKET
dc.subjectDRUG CONSUMPTION
dc.subjectDRUG INDUSTRY
dc.subjectDRUG PRICES
dc.subjectDRUG SELECTION
dc.subjectDRUG SUPPLY
dc.subjectDRUG THERAPY
dc.subjectDRUGS
dc.subjectDUMPING
dc.subjectECONOMIC GROWTH
dc.subjectEMERGENCY CARE
dc.subjectENTITLEMENT
dc.subjectEQUAL ACCESS
dc.subjectESSENTIAL DRUGS
dc.subjectESSENTIAL MEDICINES
dc.subjectEXPENDITURE
dc.subjectEXPENDITURES
dc.subjectFAMILIES
dc.subjectFAMILY MEMBERS
dc.subjectFRAUD
dc.subjectGMP
dc.subjectGOOD MANUFACTURING PRACTICES
dc.subjectHEALTH CARE
dc.subjectHEALTH CENTERS
dc.subjectHEALTH FACILITIES
dc.subjectHEALTH INSTITUTIONS
dc.subjectHEALTH INSURANCE
dc.subjectHEALTH OUTCOMES
dc.subjectHEALTH PLANS
dc.subjectHEALTH POLICY
dc.subjectHEALTH RISKS
dc.subjectHEALTH SECTOR
dc.subjectHEALTH SERVICE
dc.subjectHEALTH SERVICE PROVIDERS
dc.subjectHEALTH SERVICES
dc.subjectHEALTH SYSTEM
dc.subjectHEALTH WORKERS
dc.subjectHEALTHCARE
dc.subjectHERBAL PRODUCTS
dc.subjectHOSPITAL
dc.subjectHOSPITAL PHARMACIES
dc.subjectHOSPITALS
dc.subjectINSURANCE COVERAGE
dc.subjectINSURANCE SCHEMES
dc.subjectINSURERS
dc.subjectINTERNATIONAL MARKET
dc.subjectINTERNATIONAL ORGANIZATIONS
dc.subjectINVENTORY
dc.subjectINVENTORY MANAGEMENT
dc.subjectIRRATIONAL USE
dc.subjectLACK OF COMMUNICATION
dc.subjectLAND OWNERSHIP
dc.subjectLEGAL FRAMEWORK
dc.subjectLIFE SAVING
dc.subjectLIMITED RESOURCES
dc.subjectLOCAL MANUFACTURERS
dc.subjectLOW-INCOME COUNTRIES
dc.subjectMALARIA
dc.subjectMANAGEMENT SYSTEMS
dc.subjectMARKET DISTORTION
dc.subjectMARKET RESEARCH
dc.subjectMARKET RESEARCH FIRM
dc.subjectMARKET SHARE
dc.subjectMEDICAL DEVICES
dc.subjectMEDICAL SCHOOL
dc.subjectMEDICATION
dc.subjectMEDICINE
dc.subjectMEDICINES
dc.subjectMICROBIOLOGY
dc.subjectMIDWIVES
dc.subjectMINISTRIES OF HEALTH
dc.subjectMINISTRY OF HEALTH
dc.subjectNATIONAL AIDS
dc.subjectNATIONAL DRUG
dc.subjectNATIONAL HEALTH POLICY
dc.subjectPATIENT
dc.subjectPATIENTS
dc.subjectPAYMENT TERMS
dc.subjectPHARMACEUTICAL
dc.subjectPHARMACEUTICAL CONSUMPTION
dc.subjectPHARMACEUTICAL EXPENDITURE
dc.subjectPHARMACEUTICAL INDUSTRY
dc.subjectPHARMACEUTICAL MANUFACTURERS
dc.subjectPHARMACEUTICAL POLICY
dc.subjectPHARMACEUTICAL REGULATION
dc.subjectPHARMACEUTICAL SECTOR
dc.subjectPHARMACEUTICAL SUPPLY
dc.subjectPHARMACEUTICALS
dc.subjectPHARMACISTS
dc.subjectPHARMACY
dc.subjectPHYSICIANS
dc.subjectPOLICY DIALOGUE
dc.subjectPOLICY FRAMEWORK
dc.subjectPOLICY GOALS
dc.subjectPOLICY IMPLICATIONS
dc.subjectPOLICY MAKERS
dc.subjectPOLITICAL SUPPORT
dc.subjectPOOLED PROCUREMENT
dc.subjectPRESCRIPTIONS
dc.subjectPRICE COMPETITION
dc.subjectPRICE LEVEL
dc.subjectPRICE LEVELS
dc.subjectPRIVATE PHARMACIES
dc.subjectPROCUREMENT
dc.subjectPROGRESS
dc.subjectPSYCHOTROPIC DRUGS
dc.subjectPUBLIC DEBATE
dc.subjectPUBLIC HEALTH
dc.subjectPUBLIC PHARMACIES
dc.subjectPUBLIC PHARMACY
dc.subjectPURCHASING
dc.subjectPURCHASING POWER
dc.subjectQUALITY ASSURANCE
dc.subjectQUALITY CONTROL
dc.subjectRATIONAL DRUG USE
dc.subjectRATIONAL USE OF DRUGS
dc.subjectREGIONAL HOSPITAL
dc.subjectREGULATORY AGENCIES
dc.subjectRESPECT
dc.subjectRETAIL
dc.subjectRETAIL PHARMACIES
dc.subjectRETAIL PRICE
dc.subjectRETAIL PRICES
dc.subjectROLE MODELS
dc.subjectRURAL AREAS
dc.subjectSALE
dc.subjectSALES
dc.subjectSCREENING
dc.subjectSELFMEDICATION
dc.subjectSERVICE DELIVERY
dc.subjectSERVICE DELIVERY POINTS
dc.subjectSERVICE FACILITIES
dc.subjectSTANDARD TREATMENT GUIDELINES
dc.subjectSTOCKS
dc.subjectSUPPLIER
dc.subjectSUPPLIERS
dc.subjectSUPPLY CHAIN
dc.subjectSUPPLY CHAIN MANAGEMENT
dc.subjectSUPPLY CHAINS
dc.subjectSUPPLY MANAGEMENT
dc.subjectTECHNICAL ASSISTANCE
dc.subjectTENDERING
dc.subjectTHERAPEUTICS
dc.subjectTOTAL SALES
dc.subjectTREATMENT PREFERENCES
dc.subjectTREATMENTS
dc.subjectTURNOVER
dc.subjectURBAN AREAS
dc.subjectVISITS
dc.subjectVITAMINS
dc.subjectWAREHOUSE
dc.subjectWHOLESALER
dc.subjectWHOLESALERS
dc.subjectWORKERS
dc.subjectWORKING CONDITIONS
dc.subjectWORLD HEALTH ORGANIZATION
dc.titleThe Pharmaceutical Sector in Ghanaen
dc.typePolicy Noteen
dc.typeDocument de politique généralefr
dc.typeDocumento de políticases
dspace.entity.typePublication
okr.crossref.titleThe Pharmaceutical Sector in Ghana
okr.date.disclosure2013-09-12
okr.date.doiregistration2025-05-07T10:46:41.015444Z
okr.doctypeEconomic & Sector Work::Policy Note
okr.doctypeEconomic & Sector Work
okr.docurlhttp://documents.worldbank.org/curated/en/734211468030342727/The-pharmaceutical-sector-in-Ghana-policy-note
okr.guid734211468030342727
okr.identifier.externaldocumentum000356161_20130912164522
okr.identifier.internaldocumentum18241232
okr.identifier.report81022
okr.importedtrue
okr.language.supporteden
okr.pdfurlhttp://documents.worldbank.org/curated/en/734211468030342727/pdf/810220WP0Ghana0900PUBLIC0Box379825B.pdfen
okr.region.administrativeAfrica
okr.region.countryGhana
okr.topicHealth, Nutrition and Population::Health Monitoring & Evaluation
okr.topicHealth, Nutrition and Population::Pharmaceuticals & Pharmacoeconomics
okr.topicHealth, Nutrition and Population::Population Policies
okr.topicLaw and Development::Health Law
okr.topicMacroeconomics and Economic Growth::Markets and Market Access
relation.isAuthorOfPublication8d6fe777-ecd9-594f-ad71-6caae07af3f6
relation.isAuthorOfPublication.latestForDiscovery8d6fe777-ecd9-594f-ad71-6caae07af3f6
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
810220WP0Ghana0900PUBLIC0Box379825B.pdf
Size:
854.63 KB
Format:
Adobe Portable Document Format
Download
No Thumbnail Available
Name:
810220WP0Ghana0900PUBLIC0Box379825B.txt
Size:
127.44 KB
Format:
Plain Text
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download
Collections
Policy Notes